Latest news with #GaryJacob
Associated Press
19-05-2025
- Business
- Associated Press
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob's presentation will cover the development of urcosimod, OKYO's lead clinical drug candidate, to treat neuropathic corneal pain (NCP) which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort. Presentation Information: Event: 4th Annual GPCRs-Targeted Drug Discovery Summit Presenter: Dr. Gary S. Jacob, CEO of OKYO Pharma Presentation Title: Clinical Development of Urcosimod, Targeting CMKLR1 (ChemR23), to Treat Neuropathic Corneal Pain Date: Thursday, May 22, 2025 Location: Revere Hotel Boston Common, Boston, MA About Neuropathic Corneal Pain (NCP) NCP is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but is thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated, with limited success, by various topical and systemic treatments in an off-label fashion. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a just-completed randomized, placebo-controlled, double-masked Phase 2 trial involving 17 neuropathic corneal pain patients. About OKYO OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and ocular diseases. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients in a Phase 2 trial. For further information, please visit Enquiries:
Yahoo
08-05-2025
- Entertainment
- Yahoo
Abbey Road on the River to remain in Louisville area for 10 more years. What to know
Abbey Road on the River, the five day celebration of peace, love, and Beatles music held annually in Jeffersonville, Indiana, will continue through 2035 and perhaps beyond. The festival's producer, Gary Jacob, has renewed a 10-year partnership between the festival, the City of Jeffersonville, and Southern Indiana Tourism. For 23 years, Abbey Road on the River has captivated fans with an immersive, Beatles-centered experience and world-class performances where attendees enjoy interactive Beatles-themed art installations and music memorabilia. "Ten years sounds about right. If Paul and Ringo are still performing into their 80s, I figure at 76, I can keep going too,' Jacob said in a release. "This festival belongs in Jeffersonville. The city, the fans, the spirit — it all comes together here in the most beautiful way. With this agreement, we can dream even bigger." More: Waterfront Wednesday is back! Here's the 2025 lineup for the free Louisville concert series The festival annually hosts fans from across the world each Memorial Day weekend and is one of Southern Indiana's top tourism events. The event generates millions of dollars in economic activity while supporting hotels, restaurants, and local shops. 'This festival is part of Jeffersonville's heartbeat,' said Jeffersonville Mayor Mike Moore. 'Abbey Road on the River brings people together, fills our city with joy, and gives us something to be proud of. It's part of who we are now, and I'm thrilled it will continue for another decade.' Here's what to know about the 2025 Abbey Road on the River music festival: The 2025 festival is planned for May 22-26 and will be held at Jeffersonville's Big Four Station Park. The 2025 festival will feature more than 200+ acts including The Love Concert, Classicstone, The Jukebox Beatles from Puerto Rico, The LSB Experience, and Grammy winner and lead Guitarist for Wings, Laurence Juber. More: The Big Stomp Music Festival announces its 2025 lineup. Here's who is performing Tickets for the 2025 Abbey Road on the River are available at or at the SoIN Visitors Center, 228 Spring St., Jeffersonville, Indiana. Reach features reporter Kirby Adams at kadams@ This article originally appeared on Louisville Courier Journal: Abbey Road on the River festival: dates, tickets, performers
